Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 102Thyroid Neoplasms 40Thyroid Cancer, Papillary 36Carcinoid Tumor 32Neoplasms 28Multiple Endocrine Neoplasia Type 1 22Adenocarcinoma, Follicular 22Thyroid Carcinoma, Anaplastic 21Neoplasm Metastasis 21Pituitary Neoplasms 20Carcinoma, Neuroendocrine 20Pheochromocytoma 19Carcinoma, Medullary 19Paraganglioma 17Carcinoma, Non-Small-Cell Lung 17Somatostatinoma 16Adrenocortical Carcinoma 16Pancreatic Neoplasms 14Carcinoma, Islet Cell 14Insulinoma 12Glucagonoma 12Adenoma, Islet Cell 12Gastrinoma 11Colorectal Neoplasms 11Breast Neoplasms 11Sarcoma 10Melanoma 10Gastro-enteropancreatic neuroendocrine tumor 10Carcinoma, Renal Cell 10Pituitary ACTH Hypersecretion 9

Interventions

pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Nelson Syndrome × Endocrine × Clear all
NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Novartis

Phase 2 Terminated
118 enrolled 11 charts
EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡